Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Secondary malignant neoplasm of colon and/or rectum
0.090 GeneticVariation BEFREE Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study). 27878354 2017
Secondary malignant neoplasm of colon and/or rectum
0.090 GeneticVariation BEFREE This meta-analysis demonstrates no significant difference between KRAS G13D and other KRAS MT tumours in terms of treatment benefit from anti-EGFR mAbs for mCRC. 26812186 2016
Secondary malignant neoplasm of colon and/or rectum
0.090 GeneticVariation BEFREE In patients with G13D-mutated chemotherapy-refractory mCRC, there was no statistically significant improvement in disease control at 6 months with either cetuximab monotherapy or cetuximab plus irinotecan. 27114605 2016
Secondary malignant neoplasm of colon and/or rectum
0.090 GeneticVariation BEFREE ICECREAM is a randomised, phase II, open-label, controlled trial comparing the efficacy of cetuximab alone or with irinotecan in patients with "quadruple wild type" or G13D-mutated metastatic colorectal cancer, whose disease has progressed on, or who are intolerant of oxaliplatin- and fluoropyrimidine-based chemotherapy. 27246726 2016
Secondary malignant neoplasm of colon and/or rectum
0.090 GeneticVariation BEFREE Patients who had mCRC with the KRAS p.G13D mutation appeared to benefit more from cetuximab than patients who had tumors with KRAS codon 12 mutations. 22972628 2013
Secondary malignant neoplasm of colon and/or rectum
0.090 GeneticVariation BEFREE This retrospective pooled analysis suggests comparable efficacy of cetuximab-based and bevacizumab-based first-line therapy in patients with p.G13D mutant mCRC. 22441566 2012
Secondary malignant neoplasm of colon and/or rectum
0.090 GeneticVariation BEFREE Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. 22537608 2012
Secondary malignant neoplasm of colon and/or rectum
0.090 GeneticVariation BEFREE Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. 22734028 2012
Secondary malignant neoplasm of colon and/or rectum
0.090 GeneticVariation BEFREE Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. 20978259 2010